secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001437749-24-032770
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences: nano-PFA reduces benign thyroid nodule volume >50% in feasibility study
--------------------------------------------------------------------------------

- First-in-human study (30 patients) shows ≥50% nodule volume reduction and symptomatic relief within 1 month.
- Results presented at 2024 American Thyroid Association Annual Meeting by PI Dr. Stefano Spiezia.
- No residual fibrosis or scarring observed; potential advantage over thermal ablation and surgery.
- Company plans to commence pivotal trial mid-2025 to support U.S. labeling indication.
- Study NCT06117085 fully enrolled; long-term follow-up ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924032770/0001437749-24-032770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924032770/plse20241031c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-032770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer